GlassScriptPhysician profile
Joan Newell
NPI 1487829503
$2,585.23
in general payments reported to CMS, 2019-2025
24 companies · $721 in 2025
The $721 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $82.65 · 2021: $15.12 · 2022: $149 · 2023: $799 · 2024: $676 · 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,195.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $437.31 | 2023-2025 | |
| Abbott Laboratories | $421.07 | 2023-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $320.46 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $192.65 | 2020-2025 | Otezla, Repatha, Evenity |
| Novo Nordisk INC | $173.71 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $147.41 | 2019-2025 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.13 | 2019-2024 | Spiriva Respimat, Stiolto Respimat |
| Pfizer INC. | $127.70 | 2022-2025 | |
| Astellas Pharma US INC | $110.68 | 2023-2024 | Veozah |
| Exact Sciences Corporation | $96.69 | 2023-2024 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $85.77 | 2024-2025 | Gemtesa |
| Corcept Therapeutics | $70.37 | 2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $38.39 | 2019-2023 | Trintellix |
| Lundbeck LLC | $28.20 | 2023 | Rexulti |
| Novartis Pharmaceuticals Corporation | $27.00 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $26.71 | 2025 | Inspire |
| Insulet Corporation | $24.52 | 2025 | Omnipod |
| Phathom Pharmaceuticals, INC. | $22.86 | 2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $20.62 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $19.59 | 2023 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $18.53 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.78 | 2024 | Xifaxan |
| Lilly USA, LLC | $14.60 | 2022 | |
| Merck Sharp & Dohme LLC | $12.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joan Newell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.